Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S.
Oh ST, et al. Among authors: harder bg.
Blood Adv. 2023 Oct 10;7(19):5835-5842. doi: 10.1182/bloodadvances.2023010151.
Blood Adv. 2023.
PMID: 37552106
Free PMC article.